IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production

Nucleic Acid Therapeutics
Jason D FerroneA Robert MacLeod

Abstract

Kallikrein is the key contact system mediator responsible for the conversion of high-molecular-weight kininogen into the inflammatory vasodilator peptide bradykinin, a process regulated by C1-esterase inhibitor (C1-INH). In hereditary angioedema (HAE), genetic mutations result in deficient or dysfunctional C1-INH and dysregulation of the contact system leading to recurrent, sometimes fatal, angioedema attacks. IONIS-PKKRx is a second-generation 2'-O-(2-methoxyethyl)-modified chimeric antisense oligonucleotide, designed to bind and selectively reduce prekallikrein (PKK) mRNA in the liver. IONIS-PKKRx demonstrated dose-dependent reduction of human prekallikrein hepatic mRNA and plasma protein in transgenic mice and dose- and time-dependent reductions of plasma PKK in Cynomolgus monkeys. Similar dose-dependent reductions of plasma PKK levels were observed in healthy human volunteers accompanied by decreases in bradykinin generation capacity with an acceptable safety and tolerability profile. These results highlight a novel and specific approach to target PKK for the treatment of HAE and other diseases involving contact system activation and overproduction of bradykinin.

References

Jan 1, 1997·ILAR Journal·J. Derrell ClarkDennis F. Kohn
Dec 1, 2001·Archives of Internal Medicine·U C NzeakoW J Tremaine
Apr 1, 1955·The Journal of Clinical Investigation·O D RATNOFF, J E COLOPY
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard S GearyArthur A Levin
Aug 5, 2008·Molecular Immunology·Alvin E DavisFengxin Lu
Sep 5, 2008·The New England Journal of Medicine·Bruce L Zuraw
Sep 16, 2010·International Journal of Laboratory Hematology·A BowyerM Makris
Aug 6, 2013·Methods in Molecular Biology·Rosanne M Crooke, Mark J Graham
Aug 14, 2013·PloS One·Federica DefendiUNKNOWN National Reference Centre for Angioedema CREAK
Dec 2, 2014·Journal of the American Chemical Society·Jayaprakash K NairMuthiah Manoharan
Nov 14, 2015·Journal of Thrombosis and Haemostasis : JTH·Alvin H Schmaier
Dec 29, 2015·Journal of Thrombosis and Haemostasis : JTH·Andrew T LongThomas Renné
Jul 1, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stanley T CrookeSanjay Bhanot
Oct 13, 2016·Annual Review of Pharmacology and Toxicology·C Frank BennettRichard S Geary
Feb 23, 2017·The New England Journal of Medicine·Aleena BanerjiBurt Adelman
Jul 9, 2017·Immunology and Allergy Clinics of North America·Meng Chen, Marc A Riedl
Dec 1, 2017·Nucleic Acid Therapeutics·Stanley T CrookeSanjay Bhanot
Apr 5, 2018·Cell Metabolism·Stanley T CrookeBrenda F Baker
Jul 24, 2018·The Journal of Allergy and Clinical Immunology. in Practice·Marco Cicardi, Bruce L Zuraw
Jul 26, 2018·The New England Journal of Medicine·Emel Aygören-PürsünMarco Cicardi
Nov 28, 2018·JAMA : the Journal of the American Medical Association·Aleena BanerjiUNKNOWN HELP Investigators

❮ Previous
Next ❯

Citations

Dec 5, 2019·Blood·Ivan IvanovDavid Gailani
Sep 3, 2020·The New England Journal of Medicine·Danny M CohnErik S G Stroes
Jun 26, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Aniket WahaneRaman Bahal
Feb 19, 2021·The Journal of Biological Chemistry·Stanley T CrookeRosanne M Crooke
Mar 26, 2021·Nature Reviews. Drug Discovery·Stanley T CrookeXue-Hai Liang
Mar 3, 2020·Thérapie·Marion LepelleyLaurence Bouillet
Aug 18, 2020·Biochemical Pharmacology·Stanley T CrookeRichard S Geary
Aug 2, 2021·Molecular Aspects of Medicine·Manish PandeyGeetanjali Chawla

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA
PCR
antisense

Software Mentioned

[UNK]
SAS

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.